Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 13 EP applications Frédéric Didelon has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after October 14, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12736001

METHOD FOR TREATING METABOLIC DISORDERS

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12762605

ALISPORIVR FOR TREATMENT OF HEPATIS C VIRUS INFECTION

IPC classification:
A61K 38/13, A61K 31/14
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12727081

METHODS OF TREATING PSORIATIC ARTHRITIS (PSA) USING IL-17 ANTAGONISTS AND PSA RESPONSE OR NON- RESPONSE ALLELES

IPC classification:
A61K 39/395, G01N 33/564, C12Q 1/68, C07K 16/24
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13722740

PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES

IPC classification:
C07K 7/64
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13814523

ACUTE KIDNEY INJURY

IPC classification:
G01N 33/68
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13717513

IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION

IPC classification:
G01N 33/569, C12Q 1/68, G01N 33/50
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14756126

METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS (GPP) USING IL-17 ANTAGONISTS

IPC classification:
A61K 39/00, C07K 16/24, A61K 39/395
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP16163440

METHODS OF TREATING ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS USING ANTI-IL-17 ANTIBODIES

IPC classification:
A61P 37/06, A61K 31/519, C07K 16/24, A61K 39/395
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
Examination is in progress
EP15722260

METHODS OF IMPROVING OR ACCELERATING PHYSICAL RECOVERY AFTER SURGERY FOR HIP FRACTURE

IPC classification:
C07K 16/28, C07K 16/18, A61K 39/00
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16166665

IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS

IPC classification:
C07C 251/54, C07C 251/52, C07C 251/48, C07D 333/22, C07D 333/16, C07D 333/12, C07D 307/52, C07D 307/12, C07D 307/10, C07D 295/06, C07D 217/04, C07D 213/61, C07D 213/53, C07D 213/30, C07D 211/60, C07D 207/16, C07D 205/04, A61K 31/135, C07D 211/28
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
APPLICATION PUBLISHED
EP15767597

USE OF IL-17 ANTAGONISTS TO INHIBIT THE PROGRESSION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS PATIENTS

IPC classification:
C07K 16/24, A61K 39/00
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
Request for examination was made
EP15816531

MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA

IPC classification:
A61K 39/395, A61P 21/00
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
Request for examination was made
EP16766396

THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USING THE ANTIBODIES

IPC classification:
A61P 37/08, A61P 11/06, A61K 9/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Frédéric Didelon, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature